GIKLY News and Press, Grifols SA Barcelona ADR From 12/22/23

2023-12-22 17:56:28 ET Summary The biotech bear market has presented investment opportunities for investors to take meaningful stakes in public companies at venture valuations. AI drug discovery has faced setbacks in the past 18 months, but Gain Therapeutics' has found success usi...

2023-12-08 17:34:26 ET Summary Argenx's failure removes competitive pressure on Grifols' immunoglobulin franchise. Grifols is in advanced negotiations to sell Shanghai RAAS, which would eliminate short-term debt concerns. Grifols' Q3 results showed increased sales, improved EB...

2023-11-29 08:21:29 ET More on Grifols Grifols, S.A. (GRFS) Q3 2023 Earnings Call Transcript Grifols: Cheap For A Reason Historical earnings data for Grifols, S.A. Financial information for Grifols, S.A. Historical earnings data for Grifols, S.A. ...

2023-11-02 22:33:06 ET Grifols, S.A. (GRFS) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Nuria Pascual - IR and Sustainability Officer Thomas Glanzmann - Executive Chairman and CEO Victor Grifols Deu - COO Alfredo Arroyo -...

2023-07-27 15:45:16 ET Grifols, S.A. (GRFS) Q2 2023 Earnings Conference Call July 27, 2023, 08:30 AM ET Company Participants Nuria Pascual - IR Thomas Glanzmann - our Executive Chairman and CEO Alfredo Arroyo - CFO Victor Grifols Deu - COO Conference Ca...

2023-07-05 10:56:31 ET Summary Grifols is a promising buy opportunity thanks to its potential to reduce its net debt/EBITDA ratio. The company's focus on deleveraging is showing results and is supported by higher savings and better margins. The plasma collection is also recovering...

2023-05-09 22:36:06 ET Grifols, S.A. (GRFS) Q1 2023 Earnings Conference Call May 9, 2023 08:30 AM ET Company Participants Nuria Pascual - IR Thomas Glanzmann - Executive Chairman Victor Grifols Deu - Co-CEO Alfredo Arroyo - CFO Conference Call Participa...

2023-03-06 09:07:53 ET Grifols ( NASDAQ: GRFS ) ( OTCPK:GIKLY ) said it entered a research, development and sublicense agreement with Selagine for developing and selling immunoglobulin eye drops for dry eye disease. Under the agreement, Selagine —  ...

The following slide deck was published by Grifols, S.A. in conjunction with their 2022 Q4 earnings call. For further details see: Grifols, S.A. 2022 Q4 - Results - Earnings Call Presentation

Grifols, S.A. (GRFS) Q4 2022 Earnings Conference Call February 28, 2023 08:30 AM ET Company Participants Nuria Pascual - IR Thomas Glanzmann - Executive Chairman Victor Grifols Deu - Co-CEO Alfredo Arroyo - CFO Conference Call Participants Peter Verdult...